A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis

Inclusion Criteria: * Has active ulcerative colitis of at least 3 months duration at screening with score of ≥2 on the endoscopy subscore of the Mayo score and baseline Mayo score of 6 to 12 * Concomitant medications: either have concurrent treatment with at least 1 of the therapies (eg, oral corticosteroids and 6-Mercaptopurine \[6-MP\]). * Has to be eligible according to the tuberculosis (TB) eligibility assessment Exclusion Criteria: * Has severe extensive colitis or ulcerative colitis limited to only the rectum or to less than 20 cm of the colon * Requires or required within 2 months prior to screening any surgery for active gastrointestinal bleeding, peritonitis (inflammation of abdominal lining), intestinal obstruction, or intra-abdominal or pancreatic abscess (a localized collection of pus in pancreas) requiring surgical drainage -Has severe fixed symptomatic stenosis (narrowing of the opening or hollow of any passage) of large or small intestine * Has colonic obstruction or history within the 6 months prior to baseline * Has colonic mucosal dysplasia (colonic mucosal cell maturation abnormality) or its history * Has a history of extensive colonic resection (extensive partial removal of colon), lymphoproliferative disease (disease in which lymphocytes are produced in excessive quantities), demyelinating disease (disease of the nervous system) * Has adenomatous colonic polyps (benign projecting mass of large intestine), stoma (opening either natural or surgically cre…